Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021.
REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 19 (Reuters) - Bristol Myers Squibb (BMY.N) said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type of kidney cancer.
"We believe this new option, given as a single injection administered in less than five minutes, could transform the treatment experience for both patients and physicians," Gina Fusaro, an executive at Bristol Myers Squibb, said.
The trial also showed a non-inferior response rate to the subcutaneous drug, compared to its intravenous form.
Bristol Myers now plans to discuss with regulators the next steps for submission and approval of subcutaneous injections for multiple types of cancers.
Persons:
Bristol Myers, Dado Ruvic, Opdivo, Gina Fusaro, Roche, Johnson, Helen Torley, Leroy Leo, Anil D'Silva, Shinjini, Shounak
Organizations:
Bristol, Bristol Myers Squibb, REUTERS, Therapeutics, U.S, Thomson
Locations:
Bengaluru